Gamida Cell
Gamida Cell Q3 FY22: net loss $17.8M; diluted EPS $0.29
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-22-072162
- Document
- 10-Q
Key figures from this report
These are the numbers Gamida Cell reported for Q3 FY22, the quarter ended Sep 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$17.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.29No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$55.1MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$14.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
